Skip to main content
SpringerLink
Log in

Active specific immunotherapy of residual micrometastasis

An evaluation of sources, doses and ratios of BCG with tumor cells

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

A vaccine of Bacillus Calmette-Guérin (BCG) admixed with tumor cells induced systemic immunity and had a therapeutic effect on subclinical, disseminated micrometastasis. Inbred strain-2 guinea-pigs given IV injections of 5×103 to 106 syngeneic L10 hepatocarcinoma cells were vaccinated after metastatic foci were established in the lung parenchyma. The purpose of this study was to establish the variables that can be manipulated to assure optimal immunotherapy while minimizing deleterious side effects of the BCG. In the present study we examined the variables of source, dose, and ratio of BCG to tumor cells. Four BCG sources (lyophilized Tice and Connaught; fresh-frozen Phipps and Tice) were compared. No significant differences among these BCG preparations could be detected with respect to adjuvant potential when they were admixed with attenuated tumor cells in a vaccine. The dose study clearly demonstrated that a BCG dose dependency exists with relation to induction of effective cell-mediated immunity or survival from disseminated micrometastatic disease. Furthermore, evaluations of dose versus ratio of BCG to tumor cells also supported a BCG dose dependency, with the lowest effective BCG dose being directly influenced by tumor burden of the host. Cutaneous reactivity and hypersensitivity of the primary and secondary immunization sites of tumor-bearing animals treated with effective and ineffective vaccines supported the direct association of reaction to BCG and specific tumor immunity. However, when an in vitro leukocyte migration inhibition assay was used, the degree of reactivity to BCG could not be exploited as a quantitative, diagnostic monitor of effective systemic tumor immunity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bartlett, G. L., Purnell, D. M., Kreider, J. W.: BCG inhibition of murine leukemia: Local suppression and systemic tumor immunity require different doses. Science 191, 299 (1976)

    Google Scholar 

  2. Bartlett, G. L., Kreider, J. W., Purnell, D. M., Hockey, A. J.: Treatment of visceral tumor with BCG-tumor cell vaccine. Cancer Immunol. Immunother. 4, 15 (1978)

    Google Scholar 

  3. Bluming, A. Z., Vogel, C. L., Ziegler, J. L., Mody, N., Kamya, G.: Immunological effects of BCG in malignant melanoma: Two modes of administration compared. Ann. Intern. Med. 76, 405 (1972)

    Google Scholar 

  4. Duncan, D. B.: Multiple range and multiple F tests. Biometrics 11, 1 (1955)

    Google Scholar 

  5. Falk, R. E., Mann, P., Langer, B.: Cell-mediated immunity to human tumors: Abrogation of serum factors and nonspecific effects of oral BCG therapy. Arch. Surg. 107, 262 (1973)

    Google Scholar 

  6. Fleiss, J. L.: Statistical methods for rates and proportions, p. 96. New York: Wiley 1973

    Google Scholar 

  7. Gutterman, J. U., Mavligit, G. M., McBride, C. M., Frei, E., III, Freireich, E. J., Hersh, E. M.: Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1973, I, 1208

    Google Scholar 

  8. Guttermann, J. U., Mavligit, G. M., Kennedy, A., McBride, C. M., Burgess, M. A., Hersh, E. M.: Immunotherapy for malignant melanoma. In: Neoplasms of the skin and malignant melanoma, p. 497. Chicago: Yearbook Medical Publishers 1976

    Google Scholar 

  9. Gutterman, J. U., Rodrigues, V., McCredie, K. B., Hester, J. P., Bodey, G. P., Freireich, E. J., Hersh, E. M.: Chemoimmunotherapy of acute myeloblastic leukemia: Four-year follow-up with BCG. In: Immunotherapy of cancer Present status of trials in man. Terry, W., Windhorst, D. (eds.), p. 375. New York: Raven Press 1978

    Google Scholar 

  10. Hanna, M. G., Jr.: Active specific immunotherapy of residual micrometastasis: A comparison of postoperative treatment with BCG-tumor cell vaccine to preoperative intratumoral BCG injection. In: Immunobiology and immunotherapy. Terry, W., Yamamura, Y. (eds.). New York: Elsevier/North-Holland 1979

    Google Scholar 

  11. Hanna, M. G., Jr., Peters, L. C.: Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vacine. Cancer Res. 38, 204 (1978a)

    Google Scholar 

  12. Hanna, M. G., Jr., Peters, L. C.: BCG immunotherapy: Efficacy of BCG-induced tumor immunity in guinea-pigs with regional tumors and/or visceral micrometastases. In: Immunotherapy of human cancer. Hersh, E. M. (ed.), p. 111. New York: Raven Press 1978b

    Google Scholar 

  13. Hanna, M. G., Jr., Peters, L. C.: Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer 42, 2613 (1979)

    Google Scholar 

  14. Hanna, M. G., Jr., Peters, L. C. Gutterman, J. U., Hersh, E. M.: Evaluation of BCG administered by scarification for immunotherapy of metastatic hepatocarcinoma in the guinea-pig. J. Natl. Cancer Inst. 56, 1013 (1976)

    Google Scholar 

  15. Hortobagyi, G. N., Richman, S. P., Dandridge, K., Gutterman, J. U., Blumenschein, G. R., Hersh, E. M.: Immunotherapy with BCG administered by scarification. Standardization of reactions and management of side effects. Cancer 42, 2293 (1978)

    Google Scholar 

  16. Jurczyk-Procyk, S., Martin, M., Dubouch, P., Gheorghiu, M., Economides, E., Khalil, A., Rappaport, H.: Toxicity studies of intravenously administered BCG in baboons. Cancer Immunol. Immunother. 1, 55 (1976)

    Google Scholar 

  17. Kabat, E. R., Mayer, M. M.: Experimental immunochemistry, p. 305. Springfield, Ill.: Thomas 1967

    Google Scholar 

  18. Khalil, A., Bourut, C., Halle-Pannenko, O., Mathé, G., Rappaport, H.: Histologic reactions of the thymus, spleen, liver and lymph nodes to intravenous and subcutaneous BCG injections. Biomedicine 22, 112 (1975)

    Google Scholar 

  19. Leibo, S. P.: Comment on the loss of immunogenicity of tumor cells caused by freezing. Cancer Immunol. Immunother. 3, 211 (1978)

    Google Scholar 

  20. McCoy, J. L., Dean, J. H., Herberman, R. B.: Human cell-mediated immunity to tuberculin as assayed by the agarose microdroplet leukocyte migration inhibition technique: Comparison with the capillary tube method. J. Immunol. Methods 15, 355 (1977)

    Google Scholar 

  21. McCoy, J. L., Brandhorst, J., Hanna, M. G., Jr.: Leukocyte migration inhibition of tumor antigen and purified protein derivative reactivity in guinea pigs sensitized to line 10 hepatocarcinoma and BCG. J. Natl. Cancer Inst. 60, 693 (1978)

    Google Scholar 

  22. Mackaness, G. B., Auclair, D. J., LaGrange, P. H.: Immunopotentiation with BCG. I. Immune response to different strains and preparations. J. Natl. Cancer Inst. 51, 1655 (1973)

    Google Scholar 

  23. McKneally, M. F., Maver, C., Kausel, H. W.: Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1976 I, 377

    Article  Google Scholar 

  24. McKneally, M. F., Maver, C., Kausel, H. W.: Intrapleural BCG immunostimulation in lung cancer. Lancet 1977 I, 593

    Google Scholar 

  25. Mangan, C., Jeglum, K. A., Sedlacek, T. V., Giuntoli, R. L., Wheeler, J. E., Rubin, E., Mikuta, J. J.: Intralymphatic BCG and the treatment of gynecologic malignancies. A phase I study. Cancer 40, 2933 (1977)

    Google Scholar 

  26. Mathé, G., Halle-Pannenko, O., Bourut, C.: BCG in cancer immunotherapy. II. Results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis and immunotherapy. Natl. Cancer Inst. Monogr. 39, 107 (1973)

    Google Scholar 

  27. Mazur, P., Leibo, S. P., Farrant, J., Chu, E. H. Y., Hanna, M. G., Jr., Smith, L. H.: Interactions of cooling rate, warming rate, and protective additive on the survival of frozen mammalian cells. In: The frozen cell. Wolstenholme, G. E. W. W., O'Connor, M. (eds.), p. 69. London: Churchill 1970

    Google Scholar 

  28. Morton, D. L., Eilber, F. R., Holmes, E. C., Hunt, J. S., Ketcham, A. S., Silverstein, M. J., Sparks, F. C.: BCG immunotherapy of malignant melanoma: Summary of seven-year experience. Ann. Surg. 180, 635 (1974)

    CAS  PubMed  Google Scholar 

  29. Morton, D. L., Eilber, F. R., Holmes, E. C., Sparks, F. C., Ramming, K. P.: Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol. Immunother. 1, 93 (1976)

    Google Scholar 

  30. Nathanson, L.: Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother. Rep. 56, 659 (1972)

  31. Peters, L. C., Brandhorst, J. S., Hanna, M. G., Jr.: The preparation of immunotherapeutic, autologous tumor cell vaccines from solid tumors. Cancer Res. (in press, 1979)

  32. Pinsky, C., Hirshaut, Y., Oettgen, H.: Treatment of malignant melanoma by intratumoral injection of BCG. Proc. Am. Assoc. Cancer Res. 13, 21 (1972)

    Google Scholar 

  33. Powles, R. L., Crowther, D., Bateman, C. J. T., Beard, M. E. J., McElwain, T. J., Russel, J., Lister, T. A., Whitehouse, J. M. A., Wrigley, P. F. M., Pike, M., Alexander, P., Fairley, G. H.: Immunotherapy for acute myelogenous leukaemia. Br. J. Cancer 28, 365 (1973)

    Google Scholar 

  34. Rapp, H. J., Churchill, W. H., Jr., Kronman, B. S., Rolley, R. T., Hammond, W. G., Borsos, T.: Antigenicity of a new diethylnitrosamine-induced transplantable guinea-pig hepatoma: Pathology and formation of ascites variant. J. Natl. Cancer Inst. 41, 1 (1968)

    Google Scholar 

  35. Ritch, P. S., McCredie, K. B., Hersh, E. M., Gutterman, J. U.: Disseminated BCG disease associated with immunotherapy by scarification in acute leukemia. Cancer 42, 167 (1978)

    Google Scholar 

  36. Rosenberg, S. A., Seipp, C., Sears, H. F.: Clinical and immunologic studies of disseminated BCG infection. Cancer 41, 1771 (1978)

    Google Scholar 

  37. Schwarzenberg, L., Simmler, M. C., Pico, J. L.: Human toxicology of BCG applied in cancer immunotherapy. Cancer Immunol. Immunother. 1, 69 (1976)

    Google Scholar 

  38. Sparks, F. C.: Hazards and complications of BCG immunotherapy. Med. Clin. North Am. 60, 499 (1976)

    Google Scholar 

  39. Sparks, F. C., Silverstein, M. J., Hunt, J. S., Haskell, C. M., Pilch, Y. H., Morton, D. L.: Complications of BCG immunotherapy in patients with cancer. N. Engl. J. Med. 289, 827 (1973)

    Google Scholar 

  40. Stein, J. A., Siletzki-Chiechanover, M., Gefel, A., Adler, A., Michaeli, D.: Untoward fatal hemorrhagic diathesis in a BCG-treated melanoma patient. Cancer Immunol. Immunother. 4, 269 (1978)

    Google Scholar 

  41. Zbar, B., Wepsic, H. T., Rapp, H. J., Borsos, T., Kronman, B. S., Churchill, W. H., Jr.: Antigenic specificity of hepatomas induced in strain-2 guinea pigs by diethylnitrosamine. J. Natl. Cancer Inst. 43, 833 (1969)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Biology Program, NCI Frederick Cancer Research Center, P.O. Box B, 21701, Frederick, Maryland, USA

    M. G. Hanna Jr., J. S. Brandhorst & L. C. Peters

Authors
  1. M. G. Hanna Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Brandhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. C. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanna, M.G., Brandhorst, J.S. & Peters, L.C. Active specific immunotherapy of residual micrometastasis. Cancer Immunol Immunother 7, 165–173 (1979). https://doi.org/10.1007/BF00199194

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199194

Keywords

Search

Navigation